DARE · NASDAQ
Dare Bioscience (DARE) Stock Price & Fundamentals
Dare Bioscience (DARE) closed at $547.37 on Oct 9, 2026, up 1.19% from the previous close of $540.94.
Share price, past year
1Y +21.17%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $547.37 |
| Sep 30, 2026 | $551.84 |
| Aug 31, 2026 | $517.31 |
| Jul 31, 2026 | $504.40 |
| Jun 30, 2026 | $500.15 |
| May 29, 2026 | $482.55 |
| Apr 30, 2026 | $465.36 |
| Mar 31, 2026 | $429.63 |
| Feb 27, 2026 | $439.78 |
| Jan 30, 2026 | $442.41 |
| Dec 31, 2025 | $425.60 |
| Nov 28, 2025 | $446.41 |
| Oct 31, 2025 | $453.51 |
Key statistics
- Market cap
- $8.30B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.66
- Revenue (TTM)
- —
- Net income (TTM)
- −$10.99M
- Shares outstanding
- 15.2M
- Dividend yield
- —
- 52-week range
- $420.90 – $555.35
Dare Bioscience's market cap is $8.30B, based on a share price of $547.37 and 15.2M shares outstanding as of Jun 30, 2026.
Financials
Dare Bioscience reported revenue of $1.03M for fiscal 2025, up 10,429.36% from fiscal 2024.
Dare Bioscience reported a net loss of $13.40M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.03M | +10,429.4% | −$13.40M | −1,300.7% | −$1.20 | −$10.27M |
| FY2024ended Dec 31, 2024 | $9.78K | −99.7% | −$4.05M | −41,430.9% | −$0.48 | $4.90M |
| FY2023ended Dec 31, 2023 | $2.81M | −71.9% | −$30.16M | −1,074.2% | −$4.15 | −$39.49M |
| FY2022ended Dec 31, 2022 | $10.00M | — | −$30.95M | −309.5% | −$4.44 | −$18.15M |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$38.70M | — | −$7.56 | −$28.78M |
| FY2016ended Dec 31, 2016 | $766.00K | +857.5% | −$672.69K | −87.8% | −$9.72 | — |
| FY2014ended Dec 31, 2014 | $80.00K | +1,233.3% | — | — | — | — |
| FY2013ended Dec 31, 2013 | $6.00K | −99.0% | — | — | — | — |
| FY2012ended Dec 31, 2012 | $625.00K | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $187.55K | −$2.98M | −$0.20 |
| Q1 FY2026ended Mar 31, 2026 | $152.46K | −$3.00M | −$0.21 |
| Q3 FY2025ended Sep 30, 2025 | $2.26K | −$3.56M | −$0.28 |
| Q1 FY2025ended Mar 31, 2025 | $25.43K | −$4.38M | −$0.50 |
| Q3 FY2024ended Sep 30, 2024 | $41.69K | −$4.70M | −$0.55 |
| Q2 FY2024ended Jun 30, 2024 | $22.44K | — | — |
| Q1 FY2024ended Mar 31, 2024 | $9.30K | — | — |
| Q4 FY2023ended Dec 31, 2023 | $1.81M | — | — |
Company profile
- Name
- Dare Bioscience, Inc.
- Ticker
- DARE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 3655 Nobel Drive, Suite 260, San Diego, CA 92122
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001401914
Recent SEC filings
- Oct 2, 2026
- Oct 1, 2026
- Sep 11, 2026
- Sep 9, 2026
- Aug 17, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jul 24, 2026
Frequently asked questions
What is Dare Bioscience's stock price?
Dare Bioscience (DARE) closed at $547.37 on Oct 9, 2026, up 1.19% from the previous close of $540.94.
What is Dare Bioscience's market cap?
Dare Bioscience's market cap is $8.30B, based on a share price of $547.37 and 15.2M shares outstanding as of Jun 30, 2026.
How much revenue does Dare Bioscience make?
Dare Bioscience reported revenue of $1.03M for fiscal 2025, up 10,429.36% from fiscal 2024.
Does Dare Bioscience pay a dividend?
Dare Bioscience's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Dare Bioscience, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures